Clinical trials for Primary peritoneal carcinoma
79 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPHASE1, PHASE2NCT07480954Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)Beijing Biotech
- RECRUITINGPHASE1, PHASE2NCT07322094CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian CancerTORL Biotherapeutics, LLC
- RECRUITINGPhase 3NCT06915025Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerImunon · PI: Premal H Thaker, M.D.
- RECRUITINGPhase 2NCT07023484Personalized Timing of Interval Debulking Surgery in Advanced Ovarian CancerThe University of Hong Kong · PI: Ka Yu Tse, MBBS, MMedSc, PhD, FRCOG
- RECRUITINGPhase 2NCT06639074Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT TrialMayo Clinic · PI: Matthew S. Block, MD, PhD
- RECRUITINGPhase 1NCT06469281A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersRegeneron Pharmaceuticals · PI: Clinical Trial Management
- RECRUITINGPhase 2NCT06492070Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological CancersEmory University · PI: Susan C Modesitt
- RECRUITINGPhase 2NCT06434610A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.Shanghai Jiaolian Drug Research and Development Co., Ltd
- RECRUITINGPhase 2NCT06420973RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 ExpressionPeking University Cancer Hospital & Institute
- ACTIVE NOT RECRUITINGPhase 1NCT06084416A Study of Sovilnesib in Subjects With Ovarian CancerVolastra Therapeutics, Inc.
- RECRUITINGPhase 2NCT05231122Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian CancerRoswell Park Cancer Institute · PI: Emese Zsiros
- RECRUITINGNCT06295965Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES StudyUniversity of Washington · PI: Elizabeth Swisher
- RECRUITINGPhase 3NCT05737303Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian CancerWomen's Hospital School Of Medicine Zhejiang University · PI: Yaxia Chen, MD
- RECRUITINGPhase 2NCT06141265Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + BevacizumabPeking University Cancer Hospital & Institute
- RECRUITINGPHASE1, PHASE2NCT05920798Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerMayo Clinic · PI: Matthew S. Block, MD, PhD
- ACTIVE NOT RECRUITINGPhase 1NCT05691504Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial CancersNational Cancer Institute (NCI) · PI: Joyce F Liu
- RECRUITINGPhase 2NCT05538091Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal CancerRonald Buckanovich · PI: Ronald J Buckanovich, MD
- RECRUITINGPhase 2NCT04919629APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant EffusionRoswell Park Cancer Institute · PI: Emese Zsiros
- RECRUITINGPHASE1, PHASE2NCT05739981Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal CancerImunon · PI: Amir Jazaeri, MD
- ACTIVE NOT RECRUITINGPhase 2NCT05605535Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian CancerCanariaBio Inc. · PI: Jada Srinivasa Rao, PhD
- ACTIVE NOT RECRUITINGPhase 1NCT05527184First in Human Study of IMGN151 in Recurrent Gynaecological CancersAbbVie · PI: ABBVIE INC.
- ACTIVE NOT RECRUITINGPhase 2NCT05446298ONC-392 and Pembrolizumab in Platinum Resistant Ovarian CancerOncoC4, Inc. · PI: Bradley Monk, MD
- RECRUITINGPHASE1, PHASE2NCT05579366Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Genmab · PI: Study Official
- RECRUITINGPhase 2NCT05465941PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube CancerMayo Clinic · PI: Andrea E. Wahner Hendrickson, M.D.
- RECRUITINGPhase 2NCT05200260Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian CancerShanghai Gynecologic Oncology Group · PI: Libing Xiang
- RECRUITINGN/ANCT05429970A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)Memorial Sloan Kettering Cancer Center · PI: Kara Long Roche, MD
- RECRUITINGPHASE1, PHASE2NCT05271318Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.TILT Biotherapeutics Ltd.
- RECRUITINGPhase 1NCT05092373Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxM.D. Anderson Cancer Center · PI: Apostolia M Tsimberidou
- ACTIVE NOT RECRUITINGPhase 2NCT04575961Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian CancerNorth Eastern German Society of Gynaecological Oncology
- RECRUITINGN/ANCT05236686Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian CancerShanghai Gynecologic Oncology Group · PI: Rongyu Zang
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05199272A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies23andMe, Inc.
- RECRUITINGNCT05129969Registry Platform Ovarian and Endometrial CanceriOMEDICO AG · PI: Thomas Decker, Prof.Dr.
- ACTIVE NOT RECRUITINGPhase 1NCT04673448Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal CancerUniversity of Washington · PI: Elizabeth M. Swisher
- ACTIVE NOT RECRUITINGPhase 2NCT04781088Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerFloor Backes, MD · PI: Floor Backes, MD
- ACTIVE NOT RECRUITINGPhase 2NCT04739800Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsNational Cancer Institute (NCI) · PI: Jung-min Lee
- RECRUITINGPhase 2NCT04716686Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous CarcinomaShandong University
- ACTIVE NOT RECRUITINGPhase 1NCT04616534Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid TumorsNational Cancer Institute (NCI) · PI: James M Cleary
- RECRUITINGPhase 2NCT04834544A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of CarePeking University Third Hospital
- ACTIVE NOT RECRUITINGPhase 2NCT04387227Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerUniversity of Washington · PI: John B. Liao
- ACTIVE NOT RECRUITINGNCT04314401National Cancer Institute "Cancer Moonshot Biobank"National Cancer Institute (NCI) · PI: Lyndsay N Harris
- RECRUITINGPhase 2NCT04469764Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial CancerJonsson Comprehensive Cancer Center · PI: Gottfried E Konecny
- ACTIVE NOT RECRUITINGPhase 3NCT04498117Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking SurgeryCanariaBio Inc. · PI: Sunil Gupta, MD, FRCPC
- ACTIVE NOT RECRUITINGPhase 1NCT04092270A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian CancerNational Cancer Institute (NCI) · PI: Rachel N Grisham
- RECRUITINGPhase 2NCT04055649ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian CancerIra Winer · PI: Ira Winer, M.D.
- ACTIVE NOT RECRUITINGN/ANCT04204811Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant ChemotherapyMemorial Sloan Kettering Cancer Center · PI: Theresa Gillis, MD
- ACTIVE NOT RECRUITINGPhase 2NCT04034927Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal CancerNational Cancer Institute (NCI) · PI: Sarah F Adams
- RECRUITINGPhase 2NCT03983226Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)Shanghai Gynecologic Oncology Group · PI: Tingyan Shi, M.D., Ph.D.
- RECRUITINGPhase 1NCT03968406Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic CancersM.D. Anderson Cancer Center · PI: Lilie L Lin
- ACTIVE NOT RECRUITINGPhase 1NCT03907527Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal CancerPrecigen, Inc · PI: Amy R. Lankford, PhD
- ACTIVE NOT RECRUITINGPhase 1NCT03586661Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube CancerM.D. Anderson Cancer Center · PI: Shannon N Westin
- ACTIVE NOT RECRUITINGPhase 2NCT03732950Pembrolizumab in Treating Participants With Recurrent Ovarian CancerJonsson Comprehensive Cancer Center · PI: Gottfried Konecny
- ACTIVE NOT RECRUITINGPhase 2NCT03579316Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerM.D. Anderson Cancer Center · PI: Shannon Westin
- ACTIVE NOT RECRUITINGPhase 2NCT03587311Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerNational Cancer Institute (NCI) · PI: Stephanie Lheureux
- ACTIVE NOT RECRUITINGPhase 3NCT03602859A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian CancerTesaro, Inc. · PI: GSK Clinical Trials
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03393884Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)Imunon · PI: Premal H. Thaker, M.D
- ACTIVE NOT RECRUITINGPhase 4NCT06972693NGS-based Germline and Somatic Genetic Test in Ovarian CarcinomaEuropean Institute of Oncology
- RECRUITINGPHASE1, PHASE2NCT03564340Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) CancersRegeneron Pharmaceuticals · PI: Clinical Trial Management
- ACTIVE NOT RECRUITINGPhase 3NCT03522246A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapypharmaand GmbH
- ACTIVE NOT RECRUITINGPhase 2NCT03355976BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell CarcinomasBrown University · PI: Don Dizon, MD
- ACTIVE NOT RECRUITINGPhase 2NCT03029403Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube CancerUniversity Health Network, Toronto · PI: Amit Oza, M.D.
- ACTIVE NOT RECRUITINGPhase 2NCT03113487P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerCity of Hope Medical Center · PI: Thanh Dellinger
- ACTIVE NOT RECRUITINGPhase 1NCT03017131Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube CancerRoswell Park Cancer Institute · PI: Emese Zsiros, MD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02650986Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1Roswell Park Cancer Institute · PI: Philip McCarthy, MD
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT02839707Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerNational Cancer Institute (NCI) · PI: Roisin E O'Cearbhaill
- ACTIVE NOT RECRUITINGPhase 1NCT02627443Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube CancerNational Cancer Institute (NCI) · PI: Andrea E Wahner Hendrickson
- ACTIVE NOT RECRUITINGPhase 2NCT02595892Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerNational Cancer Institute (NCI) · PI: Panagiotis A Konstantinopoulos
- ACTIVE NOT RECRUITINGPhase 3NCT02859038Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)Shanghai Gynecologic Oncology Group · PI: Rongyu Zang, MD,PHD
- ACTIVE NOT RECRUITINGPhase 2NCT02345265Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian CancerNational Cancer Institute (NCI) · PI: Joyce F Liu
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT02502266Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian CancerNational Cancer Institute (NCI) · PI: Jung-min Lee
- ACTIVE NOT RECRUITINGPhase 3NCT02446600Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerNational Cancer Institute (NCI) · PI: Joyce F Liu
- ACTIVE NOT RECRUITINGEarly Phase 1NCT02659241Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal CancerM.D. Anderson Cancer Center · PI: Shannon N Westin
- ACTIVE NOT RECRUITINGPhase 1NCT02208375mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianM.D. Anderson Cancer Center · PI: Shannon N Westin
- ACTIVE NOT RECRUITINGPhase 2NCT02101775Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerNational Cancer Institute (NCI) · PI: Amit M Oza
- ACTIVE NOT RECRUITINGPhase 1NCT02142803TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid TumorsNational Cancer Institute (NCI) · PI: Lakshmi Nayak
- ACTIVE NOT RECRUITINGPhase 1NCT01970722Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal CancerCity of Hope Medical Center · PI: Thanh Dellinger
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02068794MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube CancerMayo Clinic · PI: Evanthia Galanis, MD
- ACTIVE NOT RECRUITINGPhase 2NCT02124421HOT: HIPEC in Ovarian Cancer as Initial TreatmentMercy Medical Center · PI: Teresa Diaz-Montes, M.D.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT01012817Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal CancerNational Cancer Institute (NCI) · PI: Andrea E Wahner Hendrickson
- RECRUITINGNCT00488878Data Collection for Patients With Low Grade Ovarian or Peritoneal TumorsM.D. Anderson Cancer Center · PI: David M Gershenson